These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 23319492)
1. IGF2 increases de novo steroidogenesis in prostate cancer cells. Lubik AA; Gunter JH; Hollier BG; Ettinger S; Fazli L; Stylianou N; Hendy SC; Adomat HH; Gleave ME; Pollak M; Herington A; Nelson CC Endocr Relat Cancer; 2013 Apr; 20(2):173-86. PubMed ID: 23319492 [TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor (IGF) 2 stimulates steroidogenesis and mitosis of bovine granulosa cells through the IGF1 receptor: role of follicle-stimulating hormone and IGF2 receptor. Spicer LJ; Aad PY Biol Reprod; 2007 Jul; 77(1):18-27. PubMed ID: 17360960 [TBL] [Abstract][Full Text] [Related]
3. Insulin increases de novo steroidogenesis in prostate cancer cells. Lubik AA; Gunter JH; Hendy SC; Locke JA; Adomat HH; Thompson V; Herington A; Gleave ME; Pollak M; Nelson CC Cancer Res; 2011 Sep; 71(17):5754-64. PubMed ID: 21747118 [TBL] [Abstract][Full Text] [Related]
4. Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance. Locke JA; Guns ES; Lehman ML; Ettinger S; Zoubeidi A; Lubik A; Margiotti K; Fazli L; Adomat H; Wasan KM; Gleave ME; Nelson CC Prostate; 2010 Feb; 70(3):239-51. PubMed ID: 19790237 [TBL] [Abstract][Full Text] [Related]
5. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609 [TBL] [Abstract][Full Text] [Related]
6. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. Arnold JT; Le H; McFann KK; Blackman MR Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203 [TBL] [Abstract][Full Text] [Related]
8. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Locke JA; Guns ES; Lubik AA; Adomat HH; Hendy SC; Wood CA; Ettinger SL; Gleave ME; Nelson CC Cancer Res; 2008 Aug; 68(15):6407-15. PubMed ID: 18676866 [TBL] [Abstract][Full Text] [Related]
9. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells. Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705 [TBL] [Abstract][Full Text] [Related]
10. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Leon CG; Locke JA; Adomat HH; Etinger SL; Twiddy AL; Neumann RD; Nelson CC; Guns ES; Wasan KM Prostate; 2010 Mar; 70(4):390-400. PubMed ID: 19866465 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor. Plonowski A; Schally AV; Letsch M; Krupa M; Hebert F; Busto R; Groot K; Varga JL Prostate; 2002 Aug; 52(3):173-82. PubMed ID: 12111694 [TBL] [Abstract][Full Text] [Related]
12. Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline. Hsieh JT; Wu HC; Gleave ME; von Eschenbach AC; Chung LW Cancer Res; 1993 Jun; 53(12):2852-7. PubMed ID: 7684949 [TBL] [Abstract][Full Text] [Related]
13. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Culig Z; Hobisch A; Cronauer MV; Radmayr C; Trapman J; Hittmair A; Bartsch G; Klocker H Cancer Res; 1994 Oct; 54(20):5474-8. PubMed ID: 7522959 [TBL] [Abstract][Full Text] [Related]
14. cAMP-independent signaling regulates steroidogenesis in mouse Leydig cells in the absence of StAR phosphorylation. Manna PR; Chandrala SP; Jo Y; Stocco DM J Mol Endocrinol; 2006 Aug; 37(1):81-95. PubMed ID: 16901926 [TBL] [Abstract][Full Text] [Related]
15. Development of prostate cancer in a patient with primary hypogonadism: intratumoural steroidogenesis in prostate cancer tissues. Arai S; Shibata Y; Nakamura Y; Kashiwagi B; Uei T; Tomaru Y; Miyashiro Y; Honma S; Hashimoto K; Sekine Y; Ito K; Sasano H; Suzuki K Andrology; 2013 Jan; 1(1):169-74. PubMed ID: 23258647 [TBL] [Abstract][Full Text] [Related]
16. DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation. Alimirah F; Chen J; Basrawala Z; Xin H; Choubey D FEBS Lett; 2006 Apr; 580(9):2294-300. PubMed ID: 16580667 [TBL] [Abstract][Full Text] [Related]
17. Regulation of growth hormone receptors in human prostate cancer cell lines. Bidosee M; Karry R; Weiss-Messer E; Barkey RJ Mol Cell Endocrinol; 2009 Oct; 309(1-2):82-92. PubMed ID: 19540305 [TBL] [Abstract][Full Text] [Related]
18. 17beta-estradiol up-regulates the insulin-like growth factor receptor through a nongenotropic pathway in prostate cancer cells. Pandini G; Genua M; Frasca F; Squatrito S; Vigneri R; Belfiore A Cancer Res; 2007 Sep; 67(18):8932-41. PubMed ID: 17875736 [TBL] [Abstract][Full Text] [Related]
19. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers. Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342 [TBL] [Abstract][Full Text] [Related]
20. Human aortic smooth muscle cells are insulin resistant at the receptor level but sensitive to IGF1 and IGF2. Chisalita SI; Johansson GS; Liefvendahl E; Bäck K; Arnqvist HJ J Mol Endocrinol; 2009 Dec; 43(6):231-9. PubMed ID: 19589910 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]